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Gastric cancer, highly dependent on tumor angiogenesis, causes uncontrolled lethality, in part due 
to chemoresistance. Here, we demonstrate that linifanib (ABT-869), a novel multi-targeted receptor 
tyrosine kinase inhibitor, markedly augments cytotoxicity of chemotherapies in human gastric cancer. 
ABT-869 and chemotherapeutic agents exhibited a strong synergy to inhibit the viability of several 
gastric cancer cell lines, with combination index values ranging from 0.017 to 0.589. Additionally, 
the combination of ABT-869 and chemotherapeutic agents led to remarkable suppression of vascular 
endothelial growth factor (VEGF)-induced angiogenesis in vitro and in vivo. Importantly, in a preclinical 
gastric cancer xenograft mouse model, drug co-treatments led to increased mouse survival as well as a 
synergistic reduction in tumor size and the inhibition of tumor angiogenesis. Mechanistic studies further 
revealed that all of the co-treatments containing ABT-869 resulted in decreased activation of the VEGF 
receptor, the epidermal growth factor receptor and the insulin growth factor receptor. Inhibition of 
these receptor tyrosine kinases consequently attenuated the activation of the downstream AKT/mTOR 
signaling pathway both in cultured gastric cancer cells and in gastric cancer xenografts. Collectively, 
our findings suggest that the addition of ABT-869 to traditional chemotherapies may be a promising 
strategy for the treatment of human gastric cancer.
Gastric cancer is the fourth most commonly diagnosed cancer and the second most common cause of 
cancer-related death worldwide. It is a heterogeneous disease with diverse molecular and histological subtypes. 
Despite improvements in surgical and chemotherapy approaches as well as its declining incidence, gastric can-
cer remains a major global public health problem. Most recently, whole-genome sequencing studies revealed 
that several new driver genes significantly mutated in gastric cancer, including RHOA, MUC6 and CTNNA21. 
Nevertheless, only a few of these somatic alterations (such as ERBB2, ERBB3 and PI3K/AKT/mTOR) are being 
pursed clinically. Fluoropyrimidine- or platinum-based conventional cytotoxic chemotherapy is still widely 
used as the first-line treatment for gastric cancer2,3. Unfortunately, resistance to these agents as well as acquired 
multi-drug resistance with high adverse effects invariably occurs, thus limiting the efficacy of this approach. 
Identification of efficacious therapeutic interventions that sensitize gastric cancer cells to conventional treatments 
is highly desirable, and such strategies should have a significant impact on clinical settings.
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One successful treatment strategy for gastric cancer is the inhibition of angiogenesis. In addition to interrupt-
ing the supply of oxygen and nutrients in tumors, anti-angiogenesis therapy alone or in combination with other 
treatments transiently normalizes the structure and function of tumor vasculatures4. Anti-angiogenic agents can 
be used to induce the remodeling of tumor vasculature, leading to a temporary improvement in tumor perfu-
sion and re-oxygenation that potentially enhance the actions of chemotherapeutic agents. We previously showed 
that high vascular endothelial growth factor (VEGF) levels in the tumor and serum were associated with poor 
prognosis in both resectable and advanced gastric cancer5. Clinically, the addition of bevacizumab (a humanized 
anti-VEGF monoclonal antibody) or sorafenib (a small molecule tyrosine kinase inhibitor) to standard chemo-
therapy enhanced survival of advanced gastric cancer patients6,7. These impressive results indicate that the combi-
nations of anti-angiogenic inhibitors and chemotherapeutic agents are potentially effective to treat gastric cancer.
Functionally similar to sorafenib, ABT-869 is a novel orally available multi-target receptor tyrosine kinase 
(RTK) inhibitor. ABT-869 inhibits both the VEGF and platelet-derived growth factor (PDGF) receptor fami-
lies, and it exhibits potent anti-angiogenic and antitumor effects8. ABT-869 is currently in active preclinical and 
clinical cancer therapeutic development. To date, tumor regression in response to ABT-869 has been evaluated 
in multiple xenograft models9–12. Moreover, the clinical benefits of ABT-869 have been assessed in phase I to III 
trials in patients with non-small cell lung cancer, acute myeloid leukemia, colorectal cancer and hepatocellular 
carcinoma13. These trials have provided evidences for the safety and efficacy of ABT-869 treatment. However, the 
efficacy of ABT-869 in gastric cancer has not been evaluated yet. Here we test whether ABT-869 augments the 
efficacy of conventional chemotherapies in preclinical in vitro and in vivo gastric cancer models.
Our results suggest that ABT-869, when given in combination with subtoxic concentrations of 5-Fu or cis-
platin, shows significant anticancer effects with no signs of toxicity in vivo. These effects are mediated through 
targeting the receptor tyrosine kinases (VEGFR, EGFR and IGFR) and the AKT/mammalian target of rapamycin 
(mTOR) signaling cascade. This combination regimen holds promise as a potential therapeutic alternative for the 
treatment of patients with gastric cancer that is refractory to standard chemotherapy.
Results
Cytotoxic synergy of ABT-869 and chemotherapeutic agents. The cytotoxic effect of ABT-869 as a 
single agent was first evaluated in a wide spectrum of human gastric cancer cell lines. ABT-869 (chemical struc-
ture is shown in Supplementary Figure S1a) inhibited cell growth in a dose-dependent manner, with the half 
maximal inhibitory concentration (IC50) values ranging from 2.6 to 16.9 μmol/L (Supplementary Figure S1b). 
Notably, normal human gastric epithelial GES-1 cells were much resistant to ABT-869 (IC50 > 100 μmol/L), sug-
gesting that the use of ABT-869 in cancer treatment may be safe and specific to tumor cells. We also examined 
the cytotoxicity of cisplatin in a chemo-resistant gastric cancer cell line and found that SGC-7901/DDP cells were 
more than 10-fold resistant to cisplatin.
To evaluate the interaction between ABT-869 and 5-Fu or cisplatin, we examined the effect of drug 
co-treatments in gastric cancer SGC-7901cells and SGC-7901/DDP cells. The treatment of SGC-7901 cells with 
the combination of a minimally toxic dose of ABT-869 (0.05 and 0.1 μmol/L) and graded doses of 5-Fu (Fig. 1a) 
or cisplatin (Fig. 1b) resulted in decreased cell viability compared with each single agent alone. Importantly, 
similar results were also observed in chemo-resistant SGC-7901/DDP cells (Fig. 1c). We used the Fa-CI plots to 
determine the drug effectiveness and combination index (CI) values. The calculated CI values of all of the gastric 
cancer cell lines were less than 1 (ranging from 0.017 to 0.589), suggesting that ABT-869 and chemotherapies 
(either 5-Fu or cisplatin) produces a strong synergic effect in both SGC-7901 cells and SGC-7901/DDP cells.
To explore the most effective drug combinations with the highest safety margin, we used various dilutions of 
ABT-869, 5-Fu and cisplatin with concentrations below their IC50s in vitro. For the initial cytotoxic screens, we 
chose the following drug concentrations for pair-wise treatments in SGC-7901 and MGC-803 cells: ABT-869, 
0.05, 0.1 μmol/L; 5-Fu, 10 μmol/L; and cisplatin, 15 μmol/L. We treated cisplatin-resistant gastric cancer SGC-
7901/DDP cells with either 1 or 5 μmol/L of ABT-869 and 40 μmol/L of cisplatin.
ABT-869 potentiates chemotherapy-induced cell cycle arrest and apoptosis. To further explore 
the synergistic toxicity between ABT-869 and chemotherapies, we examined cell cycle arrest and apoptosis using 
flow cytometry. A number of studies have demonstrated that ABT-869 might induce either G0/G1 or S phase 
arrest14, whereas 5-Fu and cisplatin were found to induce S and G2/M phase arrest, respectively15,16. Compared 
with single agent alone, treatment with 5-Fu at the designated concentrations in the presence of a minimally toxic 
concentration of ABT-869 (e.g., 0.05 or 0.1 μmol/L) induced a significant increase in the number of cells that were 
in the S phase. Similarly, the combination of ABT-869 and cisplatin caused an almost complete arrest of cells in 
the G2/M phase (Fig. 2a). The cell cycle analysis in MGC-803 cells (Supplementary Figure S2) and BGC-823 cells 
(Supplementary Figure S3) was consistent with that in SGC-7901 cells. The pro-apoptotic effects of dual treat-
ments were next examined. As shown in Fig. 2b, ABT-869 in combination with either 5-Fu or cisplatin induced a 
significant increase in apoptosis compared with 5-Fu or cisplatin alone group in both SGC-7901 and MGC-803 
cells (P < 0.001). Similarity was also shown in AGS and BGC-823 cells (Supplementary Figure S4). To further 
investigate the inhibition of cell growth, we performed Western blotting assays to determine the mechanism of 
cell cycle arrest and apoptosis. Consistent with our observations, there was an increase in the level of cleaved 
PARP and a dose-dependent reduction in Bcl-2, Bcl-xL and CyclinD1 in co-treated SGC-7901 cells (Fig. 2c). 
Where noted, a significant synergism of pro-apoptotic action by drug pairs was also observed in SGC-7901/DDP 
cells (P < 0.001; Fig. 2d). These results suggest that ABT-869 sensitizes chemotherapeutic agents and may be use-
ful for the treatment of human gastric cancer.
Molecular basis of the effects of ABT-869 in combination with 5-Fu or cisplatin. To delineate 
the molecular mechanism by which the combination of ABT-869 and chemotherapies inhibited tumor growth, 
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we analyzed the key signaling molecules and pathways in drug-treated gastric cancer cells. Given that ABT-869 
could inhibit multiple receptor tyrosine kinases, we first examined whether the dual treatments of ABT-869 and 
chemotherapies (5-Fu and cisplatin) could effectively inhibit the specific tyrosine kinase receptors that were over-
expressed in gastric cancer. As shown in Fig. 3a (left), EGF-induced EGFR phosphorylation at Tyr1068 site was 
largely inhibited by the combined treatments, whereas no significant change of EGFR activation was observed in 
SGC-7901 cells treated with single agent alone. Notably, similar results were found for IGF1R activation (Fig. 3a, 
right). Additionally, we found that drug co-treatment also led to a significant decrease in EGFR and IGF1R levels 
in MGC-803 cells (Fig. 3b). These data suggested that ABT-869 played a critical role in the chemo-sensitization 
of gastric cancer. As a consequence of receptor inactivation, the combined treatment suppressed the phosphoryl-
ation of AKT and mTOR as well as the downstream effectors of the AKT-mTORC1 signaling such as 4EBP and 
P70S6K (Fig. 3c). These results suggest that the inactivation of EGFR and IGF1R is sufficient to block the major 
downstream survival signaling pathways. ABT-869 and 5-Fu or cisplatin lead to synergistic effects at molecular 
levels.
Synergistic effects of ABT-869 and chemotherapies on angiogenesis inhibition in vitro and 
in vivo. Given that ABT-869 is an angiogenesis inhibitor, we examined whether the migratory potential of 
HUVECs could be affected by the treatment of ABT-869 combined with traditional chemotherapies. In the 
Boyden chamber assay, HUVEC migration was not markedly affected by 5-Fu or cisplatin, whereas ABT-869 
alone caused a partial inhibition (40–50%) of endothelial cell migration (Fig. 4a). Interestingly, the combined 
treatment of ABT-869 and chemotherapies produced a dramatic suppression (80–90%) of migratory potential of 
HUVECs. We further explored the anti-angiogenic activity of the combined regimens using an in vivo angiogen-
esis model, the Matrigel plug assay. As shown in Fig. 4b, Matrigel plugs containing VEGF alone appeared dark 
red, indicating that functional vasculatures had formed inside the Matrigel through angiogenesis triggered by 
VEGF. Consistent with our in vitro findings, drug co-treatments dramatically inhibited VEGF-induced vascular 
formation, since the plugs treated with ABT-869 plus 5-Fu or ABT-869 plus cisplatin were much paler in color. 
Furthermore, we found that the synergistic effects of these drug combinations on angiogenesis inhibition were 
likely due to simultaneous inhibition of the VEGF/VEGFR2-dependent pathway in HUVECs (Fig. 4c).
Figure 1. ABT-869 synergizes with chemotherapies in gastric cancer cells. Gastric cancer cells were 
incubated with increasing concentrations of different drugs for 48 h, followed by cell viability detection. 
SGC-7901 cells were treated with drug pair of ABT-869 and 5-Fu (a) or ABT-869 and cisplatin (b). Cisplatin-
resistant SGC-7901/DDP cells were treated with ABT-869 and cisplatin (c). The drugs were added at various 
ratios as indicated in the Fa-CI plots. The combinatorial index values were calculated using CalcuSyn software. 
Fa represents the fraction affected by the dose. Dots, the means of five independent replicates; bars, standard 
deviation.
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Addition of ABT-869 to chemotherapies leads to enhanced inhibition of tumor growth and 
increased mouse survival in vivo. To expand our preclinical findings in vivo, we next investigated the 
antitumor activity of ABT-869 and chemotherapeutic agents in nude mice bearing subcutaneous human gastric 
cancer xenografts. As shown in Fig. 5a, the growth of SGC-7901 xenografts was not suppressed by either 5-Fu or 
cisplatin as a single agent at tested dosage, whereas long-lasting tumor regression occurred in the dual-treatment 
groups (P < 0.001; Fig. 5a). Specifically, 90% of the mice given combined treatments experienced complete 
tumor shrinkage as indicated by tumor volume (Fig. 5b) and tumor weight (Fig. 5c) at the end of the experiment. 
Moreover, when the skin of each mouse was pulled back to expose intact tumors, we found that the tumor growth 
suppression mediated by the drug co-treatments correlated with the level of angiogenesis inhibition (Fig. 5d). 
As a surrogate marker for survival, each mouse was sacrificed when its tumor reached approximately 1,800 mm3 
in any one dimension. Survival curves using Kaplan-Meier analysis showed that the combined therapies signifi-
cantly improved overall survival compared with single-agent or vehicle treatment (Fig. 5e). Eighty-three percent-
ages of the mice treated with ABT-869 plus 5-Fu and all of the mice treated with ABT-869 plus cisplatin survived 
for more than 60 days. Importantly, our study showed that combining ABT-869 with chemotherapies (either 5-Fu 
or cisplatin) was well tolerated in mice using the dosage and treatment schedule described above, with no weight 
loss or other noticeable signs of systemic toxicity.
Figure 2. ABT-869 potentiates cell cycle arrest and apoptosis mediated by 5-Fu or cisplatin. (a) Treatment 
with ABT-869 enhanced the cell cycle arrest triggered by 5-Fu or cisplatin. SGC-7901 cells were treated with 
the indicated concentrations of different agents alone or in combination for 48 h, followed by cell cycle analysis. 
(b) ABT-869 strengthened the apoptotic effects of 5-Fu or cisplatin. SGC-7901 and MGC-803 cells were treated 
with ABT-869 (0.1 μmol/L), 5-Fu (10 μmol/L) and cisplatin (15 μmol/L) either alone or in combination for 48 h. 
The percentage of apoptotic cells was determined by Annexin-V and propidium iodide staining. (c) ABT-869-
containing treatments resulted in increased cell cycle arrest and apoptosis, as indicated by specific molecular 
markers. The cell lysates of drug-treated SGC-7901 cells were probed for cyclin E, cyclin D, Bcl-xL, Bcl-2 and 
cleaved PARP by Western blotting assays. (d) ABT-869 promoted cisplatin-mediated cell death in a cisplatin-
resistant cell line. SGC-7901/DDP cells were treated with ABT-869 (0.1 μmol/L) and cisplatin (40 μmol/L) 
alone or in combination. Cell apoptosis analysis and live/dead staining were performed. The live cells were 
stained green and dead cells were stained red. Representative images are shown. Columns, means; bars, standard 
deviation. ***P < 0.001 vs. 5-FU or cisplatin alone group.
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Figure 3. The combined regimens decrease the RTK-mediated AKT/mTOR pathways. (a,b) ABT-869 
treatment blocked the growth factor-induced activation of EGFR and IGFR in gastric cancer cells. Serum 
starved (2% FBS, overnight) SGC-7901 cells (a) or MGC-803 cells (b) were pre-treated with ABT-869, 5-Fu and 
cisplatin alone or in combination for 24 h. The cells were then treated with EGF (50 ng/mL) or IGFII (50 ng/mL)  
for an additional 10–15 min. EGFR and IGFR phosphorylation was examined by Western blotting assays.  
(c) Treatment with ABT-869 blocked growth factor-driven activation of the AKT/mTOR signaling pathway in 
SGC-7901 cells. The cells were treated as described above and lysates were analyzed by Western blotting assays.
Figure 4. The combinations of ABT-869 and chemotherapies block VEGF-induced angiogenesis in vitro and  
in vivo. (a) ABT-869 inhibited the VEGF-induced migration of endothelial cells. Serum starved (0.5% FBS, 
overnight) HUVEC cells were exposed to ABT-869 (0.1 μmol/L), 5-Fu (10 μmol/L) and cisplatin (15 μmol/L) alone 
or in combination for 30 min. Cells were then seeded into chambers surrounded by plain endothelial cell growth 
medium or endothelial cell growth medium containing VEGF (50 ng/ml). After 6 h, the cells were fixed and stained 
with 1% crystal violet. Representative photographs were chosen from four random fields (magnification, 100x). 
(b) ABT-869 inhibited angiogenesis in a Matrigel plug assay. Six-week-old nude mice were injected with 0.4 mL of 
Matrigel containing ABT-869 (0.1 μmol/L) and/or 5-Fu (10 μmol/L) and/or cisplatin (15 μmol/L) in the presence of 
50 ng of VEGF or 20 units of heparin. After 7 d, the skin of each mouse was pulled back to expose the intact Matrigel 
plugs. Representative Matrigel plugs were photographed. (c) ABT-869 treatment suppressed the VEGF-induced 
activation of VEGFR2. Serum starved (0.5% FBS, 6 h) HUVEC cells were exposed to ABT-869 (0.1 μmol/L), 5-Fu 
(10 μmol/L) and cisplatin (15 μmol/L) alone or in combination for 1 h. Cells were then harvested and analyzed by 
Western blotting assays.
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Mechanistic analysis of xenograft tumors. To validate the molecular basis of the synergy of ABT-869 
and chemotherapies, we performed immunohistochemistry and Western blotting assays on the tumor xeno-
grafts. As shown in Fig. 6a, the levels of phosphorylated EGFR and AKT were suppressed by dual treatments. 
Additionally, the number of CD31-positive endothelial cells in the combined treatment groups was significantly 
decreased compared to that from either the vehicle control group or single-agent groups (Fig. 6a), suggesting a 
remarkable reduction of tumor neovascularization.
Western blotting analysis of protein from randomly selected tumors showed that the activity of both EGFR- 
and IGFR-mediated AKT signaling pathways was inhibited by drug co-treatments. These pathways were strongly 
suppressed by the addition of ABT-869 (Fig. 6b). In contrast, no remarkable inhibition of this pathway was 
observed when either 5-Fu or cisplatin was used as a single agent. All of these mechanistic results were consistent 
with the in vitro data shown in Fig. 3.
Discussion
5-Fu and cisplatin are currently used as first-line chemotherapy for gastric cancer patients; however, intrinsic or 
acquired resistance weakens the benefit of these approaches. Therefore, it is important to find ways to sensitize 
tumor cells to chemotherapy. Receptor tyrosine kinases (RTKs) can become abnormally activated and trigger 
downstream pathways to maintain tumor growth as well as tumor survival17,18. Moreover, a growing body of 
evidence has unveiled a correlation between EGFR-mediated mTORC2 activation and the resistance of gastric 
tumors to chemotherapy19,20. RTK blockade strategies have been shown to have a synergistic effect with chem-
otherapies in preclinical21 and clinical trials for gastric cancer7,22. Considering that angiogenesis plays a pivotal 
role in gastric cancer tumorigenesis23,24, we examined linifanib (ABT-869), a multi-RTK inhibitor9,25, to explore 
the benefit of ABT-869-containing strategies in the treatment of gastric cancer. Although ABT-869 is currently 
being examined in hepatocellular carcinoma clinical trials, no related preclinical or clinical studies have been 
carried out in gastric cancer. To the best of our knowledge, our study is the first to show the pronounced syner-
gistic effect of ABT-869 and the first-line chemotherapeutic drugs (5-Fu and cisplatin) in human gastric cancers 
(CI ranging from 0.017 to 0.589). Moreover, the cisplatin-resistant cell line SGC-7901/DDP was also vulnerable 
to ABT-869-containing treatments, as drug co-treatments strengthened cell cycle arrest and enhanced cell death 
Figure 5. ABT-869 enhances the efficacy of chemotherapeutic agents in a gastric cancer xenograft mouse 
model. SGC-7901 cancer cell subcutaneous xenografts were initiated in BALB/c nude mice (n = 10–11) and the 
mice were treated with ABT-869 (oral gavage, 10 mg/kg/day) and/or 5-Fu (i.p., 10 mg/kg/day) and/or cisplatin 
(i.p., 2 mg/kg/day) at five-day intervals for eight cycles. An equivalent amount of pure refined corn oil or dimethyl 
sulfoxide served as a vehicle control. (a) Tumor growth curves. (b) Tumor volume on day 26. (c) Tumor weight 
on day 26. (d) Representative photographs of tumor-bearing mice (Left) and representative photographs of tumor 
angiogenesis (right). (e) Combination therapies with ABT-869 prolonged mouse survival. Kaplan-Meier survival 
analysis was performed in mice whose tumor volumes reached over 1,800 mm3. Statistical comparisons were 
performed by One-way ANOVA analysis. Columns and dots, means; bars, standard deviation. *P < 0.05;  
**P < 0.01; ***P < 0.001.
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in these cisplatin-resistant gastric cancer cells (Fig. 2d). This effect may be attributed to diminished EGFR- and 
IGFR-mediated signaling pathways mediated by the ABT-869-containing therapy. Furthermore, angiogenesis 
inhibition by ABT-869 also contributed to the anti-neoplastic effects of the combined treatments. In a gastric can-
cer xenograft mouse model, ABT-869, in combination with either 5-Fu or cisplatin, blocked tumor growth and 
significantly prolonged mouse survival in vivo (Fig. 5). In addition, inhibition of the EGFR- and IGFR-mediated 
signaling pathways and angiogenesis were confirmed in the xenografts (Fig. 6). Our study is the first to show the 
validity that combining ABT-869 with chemotherapies results in a synergistic reduction in cell viability of resist-
ant gastric cells in vitro, and an increased mouse survival in vivo.
Histologically, gastric cancer can be divided into two categories: diffuse gastric cancer (DGC) and intestinal 
gastric cancer (IGC). HER2 overexpression caused by ERBB2 amplification is more prevalent in IGC than in 
DGC26. Although abnormalities in HER2 occurs in approximately 15% of gastric cancer patients27, activation of 
its downstream pathways, such as RAS/MEK/MAPK and PI3K/AKT/mTOR, are reported to be more common 
in gastric cancer tumorigenesis28. Moreover, the PI3K/AKT/mTOR signaling pathway plays a pivotal role in pri-
mary and acquired resistance in gastric cancer29–31. Activation of the PI3K/AKT/mTOR cascade can be achieved 
by the interaction between HER2 and EGFR32 or IGFR33. Therefore, blockade of either EGFR or IGFR is thought 
to be beneficial for patients whose tumors response poorly to chemotherapy. Although we found that ABT-869 
alone was insufficient to inhibit EGFR or IGFR activation that was consistent with previous findings9,25, the com-
bination of ABT-869 and first-line chemotherapies exhibited a strong inhibitory effect on both EGFR and IGFR 
as well as the downstream AKT/mTOR cascade. The detailed mechanism underlying these effects awaits further 
investigation. In addition to its effects on cell survival, the selective anti-angiogenesis effect of ABT-869 confers 
an intriguing advantage in cancers that heavily depend on angiogenesis, including gastric cancer. Moreover, the 
important role of the AKT/mTOR pathway is further supported by its crosstalk with pathways involved in the reg-
ulation of stem cell fate3. This crosstalk is reported to be involved in the epithelial-mesenchymal transition (EMT) 
process34,35. Considering the emerging roles of the EMT in chemoresistance36,37, the effect of combined therapies 
containing ABT-869 on the EMT process should be further explored in gastric cancer.
Another important issue frequently raised in the clinic is the toxicity related to single targeted agent or combi-
nation therapy. Although 5-Fu- and cisplatin-based chemotherapies benefit the overall survival of gastric cancer 
patients, unbearable renal failure and other severe adverse effects make this standard treatment not appropriate 
for all patients38–40. Therefore, the use of combination therapy to enhance the efficacy of current chemotherapies 
is extremely important. In this study, ABT-869 potentiated the effects of 5-Fu and cisplatin in both in vitro and 
Figure 6. The combinations of ABT-869 and chemotherapies block the RTK/AKT pathway in gastric 
cancer xenografts. (a) Immunohistochemical staining of p-EGFR, p-AKT and CD31. Solid tumors from 
different treatments were collected and immunohistochemistry was performed. Three tumors were randomly 
selected from different groups and representative images were shown (magnification, 400x). (b) Western 
blotting analysis of proteins in the RTK/AKT pathway was performed in xenograft lysates. Two tumors were 
randomly selected from six different groups, and the experiments were repeated three independent times with 
consistent results.
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in vivo gastric cancer models, making it possible to reduce the dosage of current chemotherapies by using drug 
combination regimens containing ABT-869. Furthermore, our results showed that the combination of ABT-869 
with either low-dose of 5-Fu or cisplatin did not lead to any obvious adverse effects in vivo, even after a 60-day 
treatment period. Unlike other multi-targeted RTK inhibitors, the selectivity of ABT-869 on VEGFR and PDGFR 
prevents many of adverse effects that typically result from RTK inhibition9,25. This is further supported by the 
finding that hepatocellular carcinoma patients are very tolerant to the ABT-869 treatment12,41.
In summary, we demonstrate that ABT-869 and chemotherapies act synergistically to inhibit the tumor growth 
and angiogenesis in vitro and in vivo through simultaneous blockade of EGFR-, IGF1R- and VEGR2-mediated 
AKT/mTOR signaling pathways. Given that ABT-869 is approved for use in clinical trials, our study provides a 
strong rationale for combining ABT-869 with current chemotherapeutic agents to treat gastric cancer patients.
Methods
Reagents and antibodies. ABT-869, 5-Fluorouracil (5-Fu) and cisplatin were purchased from Selleck 
Chemicals (Houston, TX). Recombinant human VEGF (VEGF165) was a gift from the Experimental Branch of 
the National Institutes of Health (Bethesda, MD). Recombinant human epidermal growth factor (EGF) and insu-
lin-like growth factor (IGF) were purchased from R&D Systems (Minneapolis, MN). Growth factor-reduced 
Matrigel was obtained from BD Biosciences (San Diego, CA). The following antibodies were purchased from Cell 
Signaling Technology (Danvers, MA): VEGFR2, EGFR, IGF1R, AKT, mTOR, p70 S6K Kinase (S6K), eukaryotic 
initiation factor 4e (4EBP-1), poly (ADP-ribose) polymerase (PARP), Bcl-2, Bcl-xL, CyclinD1, phospho-specific 
anti-EGFR (Tyr1068), anti-IGF1R (Tyr1316), anti-VEGFR2 (Tyr1175), anti-AKT (Ser473), anti-mTOR (Ser2448), anti-
S6K (Ser235/236) and anti-4EBP-1 (Thr37/46). Anti-CD31 antibody was obtained from Epitomics (Burlingame, CA).
Cell lines and cell culture. Primary human umbilical vascular endothelial cells (HUVECs) were kindly 
provided by Dr. Xinli Wang (Department of Surgery, Baylor College of Medicine, Houston, TX). HUVECs were 
cultured in endothelial cell growth medium as described previously42–44: M199 medium (Gibco, Invitrogen) sup-
plemented with 20% fetal bovine serum (FBS, Hyclone Laboratories, Logan, UT), 20 μg/mL bovine endothelial 
cell growth factor (Roche Life Science), 0.1 mg/mL Heparin (Sigma), 15 mmol/L HEPES (4-(2-hydroxyethyl)-1-p
iperazineethanesulfonic acid) buffer, penicillin (50 IU/L), streptomycin (50 mg/L), NaHCO3 (44 mmol/L) and 
50 μg/mL amphotericin B. Prior written informed consent was obtained from all patients, and the study protocol 
was approved by the ethics committee of Baylor College of Medicine. The methods for HUVEC isolation were 
carried out in accordance with the NIH standards established for the human cell lines, and all of the experi-
mental protocols on HUVECs were approved by the committee of Baylor College of Medicine and East China 
Normal University. The AGS gastric cancer cell line was purchased from the American Type Culture Collection 
(Manassas, VA). The SGC-7901, MGC-803 and BGC-823 cancer cell lines were obtained from the China Center 
for Type Culture Collection (Shanghai, China). The multidrug-resistant gastric cancer cell line SGC-7901/DDP 
was purchased from Sciencell (Shanghai, China) and was routinely maintained in media containing 10 μg/mL 
diamminedichloroplatinum (Sigma, St. Louis, MO). All these gastric cancer cell lines were cultured in RPMI-
1640 medium supplemented with 10% FBS (HyClone Laboratories). A normal human gastric epithelial cell line 
(GES-1 cells) was also purchased from the China Center for Type Culture Collection and cultured in Dulbecco’s 
Modified Eagle’s Medium, supplemented with 10% FBS (HyClone Laboratories). The above cells were authenti-
cated before use by short tandem repeat analysis, and cultured at 37 °C under a humidified 95%:5% (v/v) mixture 
of air and CO2.
Cell viability assay. A cell viability assay was performed using the CellTiter 96® AQueous One Solution Cell 
Proliferation kit (Promega, Madison, WI). The half inhibitory concentration (IC50) values were calculated using 
Prism 5 (GraphPad Software, La Jolla, CA). The combination index (CI) equation, described by Chou-Talalay45, 
was generated using CalcuSyn software (Version 2; Biosoft). Combination treatments with CIs < 1 were consid-
ered to be synergistic. We determined the Fa (fraction affected by the dose) and CI values of each drug pair. All of 
the experiments were independently repeated three times.
Cell cycle analysis. After the cancer cells were treated with various drug combinations, they were fixed and 
re-suspended in a propidium iodide (PI)/RNase staining buffer (Sigma). The stained cells were then analyzed for 
DNA content using a FACScan cell analyzer equipped with Cellquest software (BD Biosciences).
Apoptosis analysis. To detect synergistic effects of the chemotherapeutic drugs on cell apoptosis, treated 
cells were analyzed using the FITC-Annexin V apoptosis kit (BD Biosciences, San Jose, CA). The results were 
analyzed by flow cytometry (FACSCalibur, BD Science). All of the experiments were independently repeated 
three times.
Live/dead staining assay. Apoptosis was examined in SGC-7901/DDP cells using a live/dead reagent 
(Invitrogen, Carlsbad, CA), which measured the intracellular esterase activity and plasma membrane integrity.
Transwell migration assay. Endothelial cell migration was assayed in Boyden chambers (BD Biosciences), 
as previously described46. Photographs of four random fields were taken using an Olympus inverted microscope, 
and the cells were quantified by manual counting based on untreated control wells. Three independent experi-
ments were performed.
Animal studies. C57BL/6 mice and BALB/cA nude mice used in the present study were purchased from 
National Rodent Laboratory Animal Resources (Shanghai, China) and maintained in a laminar airflow cabinet 
under specific pathogen-free conditions and a 12 h light–dark cycle. All treatments were administered according 
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to the NIH standards established in the Guidelines for the Care and Use of Experimental Animals. All of the 
experimental protocols were approved by the Animal Investigation Committee of East China Normal University.
Matrigel plug assay. Six to 8-week-old C57BL/6 mice were used in the Matrigel plug assay. As described 
previously47, Matrigel in the presence or absence of 50 ng VEGF and 20 units of heparin, plus the addition of 
ABT-869 (0.1 μmol/L) and/or 5-Fu (10 μmol/L) and/or cisplatin (15 μmol/L) was subcutaneously injected into 
the ventral area of C57/BL/6 mice. Seven days after the implantation, the intact matrigel plugs were carefully 
removed and imaged.
Human gastric tumor xenograft mouse model. Four to 6-week-old nude mice were used to set up gas-
tric tumor xenograft mouse model. Briefly, SGC-7901 cancer cells (3.5 × 106 cells/mouse) were subcutaneously 
injected into the right flank of each mouse. After 9 days, when the average tumor size reached approximately 
100 mm3, the mice were randomized into six groups (n = 10–11) and orally gavaged with ABT-869 (10 mg/kg/day) 
and/or intraperitoneal injected (i.p.) with 5-Fu (10 mg/kg/day) or cisplatin (2 mg/kg/day) at five-day intervals for 
eight cycles. The dosage of each drug was determined according to published literatures. An equivalent amount 
of pure refined corn oil served as a vehicle control. The tumor volumes of the xenografts were measured with 
calipers using the following formula: V = (L × [W]2) × 0.52; where L is the longest diameter of the tumor and W 
is the shortest diameter of the tumor. Twenty-six days after the initiation of treatment, tumor-bearing mice were 
imaged and a parallel western blotting experiment was performed to determine the phosphorylation levels of 
EGFR, IGFR and AKT, as well as their total protein levels (using 2 randomly selected tumor samples from each 
group). For long-term survival studies, animals were sacrificed when the tumor volumes reached 1,800 mm3. 
Tumor xenograft tissue was further processed for immunohistochemistry analysis using p-EGFR (Tyr1068), 
p-AKT (Ser473), Ki-67 and CD31 antibodies. Images were taken using a Leica DM 4000B photo microscope 
(Solms, Germany; magnification, 400x).
Western blotting analysis. The cancer cells were treated with the specified drugs and lysed in cold radi-
oimmunoprecipitation assay buffer containing a proteinase inhibitor cocktail. The protein concentrations were 
determined using the Pierce BCA Protein Assay Kit (Pierce Biotechnology, Rockford, IL) and equalized prior to 
loading. Approximately 40–50 μg of cellular protein from cells in each treatment group was applied to 6% or 10% 
SDS-polyacrylamide gels and subsequently transferred onto nitrocellulose membranes (Millipore, Billerica, MA). 
The signals were detected using the Li-Cor Odyssey Infrared system (LI-COR Biosciences, Lincoln, NE).
Statistical analysis. The data are presented as the mean ± standard deviation. Statistical tests were per-
formed using Microsoft Excel and GraphPad Prism Software version 5.0 (GraphPad Software Inc., San Diego, 
CA). For two-group comparisons, a two-tailed unpaired t-test was used. For multiple group comparisons, 
one-way ANOVA analysis was used. A value of P < 0.05 was considered to be significant. Survival curves were 
analyzed using the log-rank test (Kaplan-Meier survival curves).
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